Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection

被引：19
|
作者：
Pogorzelska, Joanna [1 ]
Flisiak, Robert [1 ]
机构：
[1] Med Univ Bialystok, Dept Infect Dis & Hepatol, 14 Zurawia St, PL-15540 Bialystok, Poland
来源：
CLINICAL AND EXPERIMENTAL HEPATOLOGY | 2016年 / 2卷 / 02期
关键词：
HCV; paritaprevir; ombitasvir; dasabuvir;
D O I：
10.5114/ceh.2016.60247
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r +/- DSV +/- RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r +/- DSV +/- RBV in clinical trials demonstrated sustained viral response (SVR) rates close to 100%. In this article we collected currently available data of 5726 patients for evaluation of OBV/PTV/r +/- DSV +/- RBV efficacy and safety in real-world experience. The sustained viral response rate in this large population was 97%, and it was exactly the same even in patients with liver cirrhotics. According to this meta-analysis, less than 3% of patients discontinued treatment due to adverse events.
引用
收藏
页码：34 / 37
页数：4
相关论文
共 50 条
  • [31] Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America
    Mendizabal, Manuel
    Haddad, Leila
    Gallardo, Patricia E.
    Ferrada, Alejandro
    Soza, Alejandro A.
    Adrover, Raul
    Aravena, Edmundo
    Roblero, Juan P.
    Prieto, Jhon
    Vujacich, Claudia
    Romero, Gustavo
    Munoz, Alberto
    Anders, Margarita
    Hernandez, Nelia
    Coccozella, Daniel
    Gruz, Fernando
    Reggiardo, Maria V.
    Ruf, Andres E.
    Varon, Adriana
    Cartier, Mariano
    Perez Ravier, Roberto
    Ridruejo, Ezequiel
    Peralta, Mirta
    Poncino, Daniel
    Vorobioff, Julio
    Aballay Soteras, Gabriel
    Silva, Marcelo O.
    JOURNAL OF MEDICAL VIROLOGY, 2017, 89 (09) : 1590 - 1596
  • [32] A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis
    Masetti, Marco
    Magalotti, Donatella
    Martino, Elena
    Andreone, Pietro
    Scuteri, Alessandra
    Zoli, Marco
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2016, 25 (04) : 559 - 561
  • [33] Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
    Danis, Nilay
    Toz, Huseyin
    Unal, Nalan
    Yilmaz, Mumtaz
    Turan, Ilker
    Gunsar, Fulya
    Karasu, Zeki
    Ersoz, Galip
    Ozkahya, Mehmet
    Akarca, Ulus Salih
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (08) : 695 - 701
  • [34] Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience
    Degertekin, Bulent
    Demir, Mehmet
    Akarca, Ulus S.
    Kani, Haluk Tarik
    Ucbilek, Enver
    Yildirim, Emre
    Guzelbulut, Fatih
    Balkan, Ayhan
    Vatansever, Sezgin
    Danis, Nilay
    Demircan, Melek
    Soylu, Aliye
    Yaras, Serkan
    Kartal, Aysun
    Kefeli, Ayse
    Gunduz, Feyza
    Yalcin, Kendal
    Erarslan, Elife
    Aladag, Murat
    Harputluoglu, Murat
    Ozakyol, Aysegul
    Temel, Tuncer
    Akarsu, Mesut
    Sumer, Hale
    Akin, Mete
    Albayrak, Bulent
    Sen, Ilker
    Alkim, Huseyin
    Uyanikoglu, Ahmet
    Irak, Kader
    Oztaskin, Sinem
    Ugurlu, Cagri Burak
    Gunes, Sevkican
    Gurel, Selim
    Nuriyev, Kenan
    Inci, Ismail
    Kacar, Sabite
    Dincer, Dinc
    Doganay, Levent
    Gokturk, Huseyin Savas
    Mert, Ali
    Cosar, Arif Mansur
    Dursun, Hakan
    Atalay, Roni
    Akbulut, Sabiye
    Balkan, Yasemin
    Koklu, Hayrettin
    Simsek, Halis
    Ozdogan, Osman
    Coban, Mehmet
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2020, 31 (12) : 883 - 893
  • [35] Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease
    Mekky, Mohamed A.
    Abdel-Malek, Mohamed O.
    Osman, Heba A.
    Abdel-Aziz, Essam M.
    Hashim, Abdel-Kader A.
    Hetta, Helal F.
    Morsy, Khairy H.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (01) : 82 - 87
  • [36] The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1
    Miyasaka, Akio
    Yoshida, Yuichi
    Yoshida, Toshimi
    Murakami, Akihiko
    Abe, Koichi
    Ohuchi, Ken
    Kawakami, Tadashi
    Watanabe, Daisuke
    Hoshino, Takao
    Sawara, Kei
    Takikawa, Yasuhiro
    INTERNAL MEDICINE, 2018, 57 (19) : 2807 - 2812
  • [37] Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection
    Keating, Gillian M.
    DRUGS, 2016, 76 (12) : 1203 - 1211
  • [38] Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort
    Said, Mohamed
    Omar, Heba
    Soliman, Zeinab
    Saad, Yasmin
    Dabes, Hosam
    Hamed, Sozan
    ElSaeed, Kadri
    ElShazly, Yehia
    ElSerafy, Magdi
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (01) : 89 - 93
  • [39] A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
    Bacinschi, Xenia
    Popescu, Gabriel Cristian
    Zgura, Anca
    Gales, Laurentia
    Rodica, Anghel
    Mercan, Adriana
    Serban, Dragos
    Haineala, Bogdan
    Toma, Letitia
    Iliescu, Laura
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [40] Real-world efficacy and safety of ombitasvir, paritaprevir/r plus dasabuvir plus ribavirin in genotype 1b patients with hepatitis C virus cirrhosis
    Preda, Carmen M.
    Popescu, Corneliu P.
    Baicus, Cristian
    Voiosu, Theodor A.
    Manuc, Mircea
    Pop, Corina Silvia
    Gheorghe, Liana
    Sporea, Ioan
    Trifan, Anca
    Tantau, Marcel
    Tantau, Alina
    Ceausu, Emanoil
    Proca, Doina
    Constantinescu, Ileana
    Ruta, Simona M.
    Diculescu, Mircea M.
    Oproiu, Alexandru
    LIVER INTERNATIONAL, 2018, 38 (04) : 602 - 610
12345